Imperial College London
Portrait Picture

Dr Paul Turner

Faculty of Medicine, National Heart & Lung Institute

Reader in Paediatric Allergy & Clinical Immunology
 
 
 
//

Contact

 

+44 (0)20 3312 7754p.turner

 
 
//

Location

 

Children's Clinical Research FacilityCambridge WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Liu:2021:10.1016/S0140-6736(21)01694-9,
author = {Liu, X and Shaw, RH and Stuart, ASV and Greenland, M and Aley, PK and Andrews, NJ and Cameron, JC and Charlton, S and Clutterbuck, EA and Collins, AM and Dinesh, T and England, A and Faust, SN and Ferreira, DM and Finn, A and Green, CA and Hallis, B and Heath, PT and Hill, H and Lambe, T and Lazarus, R and Libri, V and Long, F and Mujadidi, YF and Plested, EL and Provstgaard-Morys, S and Ramasamy, MN and Ramsay, M and Read, RC and Robinson, H and Singh, N and Turner, DPJ and Turner, PJ and Walker, LL and White, R and Nguyen-Van-Tam, JS and Snape, MD and Com-COV, Study Group},
doi = {10.1016/S0140-6736(21)01694-9},
journal = {The Lancet},
pages = {856--869},
title = {Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.},
url = {http://dx.doi.org/10.1016/S0140-6736(21)01694-9},
volume = {398},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate mass COVID-19 immunisation. However, we have previously reported that heterologous schedules incorporating an adenoviral vectored vaccine (ChAdOx1 nCoV-19, AstraZeneca; hereafter referred to as ChAd) and an mRNA vaccine (BNT162b2, Pfizer-BioNTech; hereafter referred to as BNT) at a 4-week interval are more reactogenic than homologous schedules. Here, we report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines. METHODS: Com-COV is a participant-blinded, randomised, non-inferiority trial evaluating vaccine safety, reactogenicity, and immunogenicity. Adults aged 50 years and older with no or well controlled comorbidities and no previous SARS-CoV-2 infection by laboratory confirmation were eligible and were recruited at eight sites across the UK. The majority of eligible participants were enrolled into the general cohort (28-day or 84-day prime-boost intervals), who were randomly assigned (1:1:1:1:1:1:1:1) to receive ChAd/ChAd, ChAd/BNT, BNT/BNT, or BNT/ChAd, administered at either 28-day or 84-day prime-boost intervals. A small subset of eligible participants (n=100) were enrolled into an immunology cohort, who had additional blood tests to evaluate immune responses; these participants were randomly assigned (1:1:1:1) to the four schedules (28-day interval only). Participants were masked to the vaccine received but not to the prime-boost interval. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentration (measured by ELISA) at 28 days after boost, when comparing ChAd/BNT with ChAd/ChAd, and BNT/ChAd with BNT/BNT. The heterologous schedules were considered non-inferior to the approved homologous schedules if the lower limit of the one-sided 97·5% CI of the GMR of these comparisons was greater than 0·63. The primary analysis was done in the per-protocol population, who were seronegative a
AU  - Liu,X
AU  - Shaw,RH
AU  - Stuart,ASV
AU  - Greenland,M
AU  - Aley,PK
AU  - Andrews,NJ
AU  - Cameron,JC
AU  - Charlton,S
AU  - Clutterbuck,EA
AU  - Collins,AM
AU  - Dinesh,T
AU  - England,A
AU  - Faust,SN
AU  - Ferreira,DM
AU  - Finn,A
AU  - Green,CA
AU  - Hallis,B
AU  - Heath,PT
AU  - Hill,H
AU  - Lambe,T
AU  - Lazarus,R
AU  - Libri,V
AU  - Long,F
AU  - Mujadidi,YF
AU  - Plested,EL
AU  - Provstgaard-Morys,S
AU  - Ramasamy,MN
AU  - Ramsay,M
AU  - Read,RC
AU  - Robinson,H
AU  - Singh,N
AU  - Turner,DPJ
AU  - Turner,PJ
AU  - Walker,LL
AU  - White,R
AU  - Nguyen-Van-Tam,JS
AU  - Snape,MD
AU  - Com-COV,Study Group
DO  - 10.1016/S0140-6736(21)01694-9
EP  - 869
PY  - 2021///
SN  - 0140-6736
SP  - 856
TI  - Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
T2  - The Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(21)01694-9
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34370971
UR  - https://www.sciencedirect.com/science/article/pii/S0140673621016949?via%3Dihub
UR  - http://hdl.handle.net/10044/1/91019
VL  - 398
ER  -
Download